In vitro activity of daptomycin against strains isolated from diabetic foot ulcers;Activité in vitro de la daptomycine vis-à-vis de souches cliniques isolées de plaies du pied chez des diabétiques

Pathologie Biologie

Volumn 58, Issue 1, 2010, Pages 73-77

  Sotto, A ^a   Laouini, D ^a   Bouziges, N ^a,b   Jourdan, N ^b   Richard, J L ^c   Lavigne, J P ^a,b  

^a INSERM   (France)

^b DEPARTMENT OF NEUROLOGY   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

Activit in vitro; CMI; Daptomycin; Daptomycine; Diabetic foot ulcer; In vitro activity; Infection; Infection du pied diab tique; MIC

Indexed keywords

COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; PRISTINAMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DIABETIC FOOT; DIABETIC PATIENT; DRUG INDICATION; ENTEROCOCCUS; EPSILOMETER TEST; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DIABETIC FOOT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS;

EID: 77349084642     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2009.07.038     Document Type: Article

References (37)

1. Lipsky B.A., Berendt A.R., Deery H.G., Embil J.M., Joseph W.S., Karchmer A.W., et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004, 39:885-910.
2. Lavery L.A., Armstrong D.G., Wunderlich R.P., Boulton A.J.M., Tredwell J.M. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003, 26:1435-1438.
3. Jeffcoate W.J., Lipsky B.A., Berendt A.R., Cavanagh P.R., Bus S.A., Petters E.J., et al. Unresolved issues in the management of ulcers of the foot in diabetes. Diabet Med 2008, 25:1380-1389.
4. Lavery L.A., Armstrong D.G., Wunderlich R.P., Mohler M.J., Wendel C.S., Lipsky B.A. Risk factors for foot infections in individuals with diabetes. Diabetes Care 2006, 29:1288-1293.
5. Boulton A.J.M., Vileikyte L., Ragnarson-Tennvall G., Apelqvist J. The global burden of diabetic foot disease. Lancet 2005, 336:1719-1724.
6. Mayfield J.A., Reiber G.E., Sanders L.J., Janisse D., Pogach L.M. Preventive foot care in people with diabetes. Diabetes Care 1998, 21:2161-2177.
7. Bakker K and all the members of IWGDF. International Concensus of International Working Group on the Diabetic Foot. Available from [Online 2009 June; cited 2003 May]. http://www.diabetic-foot-consensus.com/.
8. Société de Pathologie infectieuse de langue française. Management of diabetic foot infections. Med Mal Infect 2007;37:26-50.
9. Dang C.N., Prasad Y.D.M., Boulton A.J., Jude E.B. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003, 20:159-161.
10. Game F., Jeffcoate W. MRSA and osteomyelitis of the foot in diabetes. Diabet Med 2004, 21:16-19.
11. Lipsky B.A., Berendt A.R. Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev 2000, 16:S42-46.
12. Tentolouris N., Petrokkos G., Vallianou N., Zachos C., Daikos G.L., Tsapogas P., et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect 2006, 12:186-189.
13. Tentolouris N., Jude E.B., Smirnof I., Knowles E.A., Boulton A.J. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 1999, 16:767-771.
14. Sader H.S., Jones R.N. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Clin Infect Dis 2006, 43:798-799.
15. Sader H.S., Fritsche T.R., Jones R.N. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 2006, 50:2330-2336.
16. Castanheira M., Jones R.N., Sader H.S. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). Diagn Microbiol Infect Dis 2008, 61:235-239.
17. Boucher H.W., Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007, 45:601-608.
18. Alborn W.E., Allen N.E., Preston D.A. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991, 35:2282-2287.
19. Seaton R.A. Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother 2008, 62:5-23.
20. Carpenter C.F., Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis 2004, 38:994-1000.
21. Lamp K.C., Ryback M.J., Bailey E.M., Kaatz G.W. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992, 36:2709-2714.
22. Arbeit R.D., Maki D., Tally F.P., Campanaro E., Eisenstein B.I. Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681.
23. Lipsky B.A., Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005, 55:240-245.
24. Krige J.E., Linfield K., Friedrich L., Otradovec C., Martone W.J., Katz D.E., et al. Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. Curr Med Res Opin 2007, 23:2147-2156.
25. Kanafani Z.A., Corey G.R. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther 2007, 5:177-184.
26. Lipsky B.A. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2004, 20:S68-77.
27. Soussy CJ, Carret G, Cavallo JD. The Antibiotic Susceptibility Testing Committee of the French Society for Microbiology. Available from [Online: 2009 January; cited 2009 June]. http://www.sfm.asso.fr/.
28. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. CLSI document M7-A7. USA: CLSI, Wayne, PA; 2006.
29. Ge Y., MacDonald D., Hait H., Lipsky B.A., Zosloff M., Holroyd K. Microbiological profile of infected diabetic foot ulcers. Diabet Med 2002, 19:1032-1035.
30. Shankar E.M., Mohan V., Premalantha G., Srinivasan R.S., Usha A.R. Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med 2005, 16:567-570.
31. Gadepalli R., Dhawan B., Sreenivas V., Kapil A., Ammini A.C., Chaudhry R. A clinicomicrobiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care 2006, 29:1727-1732.
32. Jorgensen J.H., Crawford S.A. Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. J Clin Microbiol 2006, 44:2126-2129.
33. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007;60:788-94.
34. Goldstein E.J., Citron D.M., Nesbit C.A. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 1996, 19:638-641.
35. Hartemann-Heurtier A., Robert J., Jacqueminet S., Ha Van G., Golmard J.L., Jarlier V., et al. Diabetic foot ulcers and multidrug-resistant organisms: risk factors and impact. Diabet Med 2004, 21:710-715.
36. Richard J.L., Sotto A., Jourdan N., Combescure C., Vannereau D., Rodier M., et al. Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabetes Metab 2008, 34:363-369.
37. Eisenstein B.I. Treatment challenges in the management of complicated skin and soft tissue infections. Clin Microbiol Infect 2008, 14:17-25.